Data / Form D filings / Intellicell Biosciences, Inc.
Intellicell Biosciences, Inc.: Form D filings
Intellicell Biosciences, Inc., a biotechnology company in New York, NY, filed 6 Form D notices with the SEC between 2011 and 2012. The latest, on December 3, 2012, reports $375,000 sold of a $6 million offering to 3 investors.
Find out what Intellicell Biosciences, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 460 Park Avenue, 17th Floor, New York, NY, 10022
- Phone
- (646) 576-8700
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Nevada
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1125280
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 3, 2012 | Amendment | $6,000,000 | $375,000 | $5,625,000 | 3 | Oct 1, 2012 | sec.gov |
| Nov 13, 2012 | Amendment | $6,000,000 | $125,000 | $5,875,000 | 2 | Oct 1, 2012 | sec.gov |
| Oct 16, 2012 | New notice | $6,000,000 | $25,000 | $5,975,000 | 1 | Oct 1, 2012 | sec.gov |
| Mar 26, 2012 | Amendment | $3,500,000 | $2,475,000 | $1,025,000 | 18 | Feb 9, 2012 | sec.gov |
| Feb 23, 2012 | New notice | $3,500,000 | $2,040,000 | $1,460,000 | 13 | Feb 9, 2012 | sec.gov |
| Nov 7, 2011 | New notice | $10,000,000 | $340,000 | $9,660,000 | 3 | Oct 11, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Leonard A. Mazur | Director | |
| Myron A. Holubiak | Director | |
| Michael A. Hershman | Director | |
| Steven A. Victor | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Dec 3, 2012 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Intellicell Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.